Why insider trading matters?

When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.

- Seeking Alpha
DermTech, Inc. (DMTK)
Sector: Healthcare; Industry: Diagnostics & Research

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-05-03 Dobak John Chief Executive Officer Sell 25,000 $40.96 $1,023,930 No
2021-04-27 Dobak John Chief Executive Officer Sell 25,000 $51.35 $1,283,750 No
2021-04-12 Dobak John Chief Executive Officer Sell 25,000 $46.34 $1,158,500 No
2021-03-08 Dobak John Chief Executive Officer Sell 780 $50.04 $39,031 No
2020-12-08 Dobak John Chief Executive Officer Sell 786 $11.86 $9,322 No
2020-09-10 Dobak John Chief Executive Officer Sell 2,470 $10.82 $26,735 No

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.